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Coreceptor utilization by HIV-1 is an important determinant of pathogenesis. However, coreceptor selectivity is defined in
vitro, while in vivo critical pathogenic events occur in lymphoid tissues. Using pharmacological inhibitors, we recently
provided evidence that coreceptor selectivity by the R5X4 dual-tropic isolate 89.6 was more restricted in ex vivo infected
lymphoid tissue than in vitro [S. Glushakova, Y. Yi, J. C. Grivel, A. Singh, D. Schols, E. De Clercq, R. G. Collman, and L. Margolis
(1999). J. Clin. Invest. 104, R7–R11]. Here we extend those observations using CCR5-deficient (CCR5D32) lymphoid tissue as
well as additional primary isolates. We definitively show that neither CCR5 nor secondary coreceptors used in vitro mediate
89.6 infection in lymphoid tissue. We also demonstrate that restricted coreceptor use in lymphoid tissue ex vivo compared
with in vitro utilization occurs with other dual-tropic primary isolates and is not unique to 89.6. For all strains tested that are
dual tropic in vitro, severe CD4 T cell depletion in lymphoid tissue correlated with preferential CXCR4 use in this ex vivo
system. © 2001 Academic Press
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HIV-1 isolates can be typed by their in vitro ability to
enter and infect cells transfected with CD4 and specific
coreceptors (reviewed in Berger et al., 1999; Locati and
Murphy, 1999). Viruses that transmit infection and domi-
nate early stages of HIV disease use CCR5 [R5 variants
(Berger et al., 1998)]. HIV-1 variants isolated at late
stages of HIV disease often use CXCR4 (reviewed in
Berger et al., 1999) [X4 variants (Berger et al., 1998)].
Dual-tropic R5X4 isolates are also typical for late stages
of disease (Bjorndal et al., 1997; Connor et al., 1997;
Doranz et al., 1996; Scarlatti et al., 1997; Simmons et al.,
1996). The ability of viral isolates to use CXCR4 in vitro,
exclusively or in addition to CCR5, is associated with
massive loss of CD41 T cells in vivo and rapid progres-
sion to AIDS (Tersmette et al., 1989; Zhu et al., 1993). The
coreceptors actually used by these viruses in lymphoid
tissue, where critical events in HIV-1 disease occur,
1 To whom reprint requests may be addressed at University of Penn-
ylvania School of Medicine, 807 Abramson Building, 34th & Civic
enter Blvd., Philadelphia, PA 19104-4399. Fax: (215) 573-4446. E-mail:
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of Health, National Institute of Child Health and Human Development,
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239remain to be fully defined (Glushakova et al., 1999; Zhang
and Moore, 1999).
We previously reported that coreceptor use in vitro
was not completely predictive of coreceptor use in lym-
phoid tissue ex vivo (Glushakova et al., 1999). In partic-
ular, we found that one HIV-1 dual-tropic prototype and
one of two genetically constructed dual-tropic variants
preferentially used only one of the coreceptors in human
lymphoid tissue ex vivo, even though they were all dual-
tropic in vitro (Glushakova et al., 1999). However, these
results relied on the use of coreceptor ligands as block-
ing agents. For CXCR4, the bicyclam AMD3100 is a po-
tent and effective inhibitor. In contrast, the CCR5 ligands
including RANTES, used as a probe for CCR5 in those
tissue-based studies, do not completely inhibit replica-
tion even of monotropic R5 HIV (Glushakova et al., 1999;
Margolis et al., 1998). Whether that is because viruses
use alternative epitopes of the same receptor or because
RANTES did not saturate CCR5 in lymphoid tissue is
unknown. Alternatively, since RANTES has agonist activ-
ity and can activate at least two other chemokine recep-
tors expressed in lymphoid tissue, CCR3 and CCR1, the
effects observed could be due to factors independent of
or in addition to RANTES blockade of CCR5 (Murphy et
al., 2000).Human lymphoid tissue derived from donors geneti-
cally deficient in specific coreceptors can provide a
0042-6822/01 $35.00
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240 MALKEVITCH ET AL.novel and valuable opportunity to precisely define the
coreceptor usage and pathogenic effects of HIV-1 vari-
ants in their native lymphoid microenvironment. Here we
used tissue from a donor homozygous for the nonfunc-
tional CCR5 D32 allele to definitively establish the core-
ceptor usage by a panel of R5, X4, and R5X4 HIV-1
variants. In addition, we used the pharmacological ap-
proach to define the coreceptors used in lymphoid tissue
by two additional R5X4 primary isolates. These studies
also enabled us to address additional questions: do
R5X4 viruses all have similar cytopathic effects in lym-
phoid tissue, and is the cytopathicity of different R5X4
viruses determined by coreceptor preference? Is there
evidence for use of alternative coreceptors in primary
human lymphoid tissue? And does the D32 mutation in
CCR5 affect the functional ability of CXCR4 to mediate
HIV infection?
RESULTS
Human lymphoid tissue lacking CCR5 expression
As part of our standard analysis of tonsillar tissues
obtained for experiments under approved protocols, lym-
phocytes are mechanically isolated from the tissues,
stained for CD45, CD4, CD8, CCR5, and CXCR4, and
analyzed by flow cytometry. By this analysis, we identi-
fied a donor tissue that did not express CCR5 (Fig. 1a). To
test the donor’s CCR5 genotype, we used a primer pair
that spans the 32-bp deletion in the common CCR5D32
FIG. 1. Phenotypic and genotypic analysis of CCR5D32 lymphoid tis
tissue and stained for CD3, CD4, CD8, CCR5, and CXCR4. The right pan
tissue, and the left panel shows CD41 T cells from a tissue donor that l
ene was carried out on DNA obtained from tonsillar tissue from the do
arried out in parallel using DNA from PBMC of two other donors of k
2/2). On the right are shown the sizes of the wild-type (312 bp) anddeletion allele and performed PCR amplification of
genomic DNA isolated from whole tonsillar tissue. Theseamplification products were compared with those from
two unrelated individuals of known CCR5 genotype (Fig.
1b). This genotypic analysis indicated that the donor was
homozygous for the CCR5D32 mutation and confirms our
phenotypic results since CCR5D32 homozygotes are
known not to express detectable CCR5 on the surface of
peripheral blood lymphocytes (Wu et al., 1997). It also
extends those previous observations by showing, as
expected, that lymphocytes in lymphoid tissues from
these individuals also do not express surface CCR5.
Replication of monotropic X4 and R5 HIV-1 variants in
CCR5D32 lymphoid tissue
Since the lymphoid microenvironment is where critical
pathogenic events take place in vivo and coreceptor use
is a central determinant of pathogenesis, we utilized the
CCR5-negative lymphoid tissue to definitively establish
coreceptor selectivity profiles of a panel of viruses that
we have previously studied using pharmacologic inhibi-
tors. SF162 is classified as a monotropic R5 virus in
transfected cell line assays. We inoculated CCR5D32
and control (normal) tissue with SF162 and evaluated its
replication. In 11 experiments with normal tissue, the
total production of p24 per tissue block ranged from 1 to
39 ng. In contrast, SF162 did not replicate at all in tissue
lacking CCR5 (Fig. 2a), confirming this isolate’s exclusive
reliance on CCR5 in the lymphoid environment. We also
tested whether in CCR5D32 tissue CXCR4 remains func-
tional as a coreceptor for X4 HIV-1. We inoculated normal
) Phenotypic analysis. Cells were mechanically isolated from tonsillar
s a representative analysis of CD41 T cells isolated from normal donor
CR5 expression. (b) Genotypic analysis. PCR amplification of the CCR5
own in (a) who was found to lack CCR5 expression. Amplification was
enotype including CCR5 wild-type (1/1) and CCR5D32 homozygous
80 bp) CCR5 amplicons.sue. (a
el show
acks C
nor shand CCR5D32 tissue with the X4 variant LAV.04 and
evaluated its replication. In 18 experiments with normal
entage
241CORECEPTOR USE BY HIV-1 IN CCR5D32 LYMPHOID TISSUEtissue, the total production of p24 per block for LAV.04
ranged from 20 to 48 ng/block. Neither the kinetics of
LAV.04 replication nor the total amount of p24 produced
by CCR5D32 tissue differed from those parameters in
normal tissue (Fig. 2b), suggesting that CXCR4 corecep-
tor function is not affected by the absence of CCR5.
Inoculation of 89.6 and its isogenic chimeras in
CCR5D32 human tonsillar tissue
To definitively establish whether HIV-1 variants that
utilize multiple coreceptors in vitro, including both CCR5
and CXCR4, also do so in the context of human lymphoid
tissue, we used the CCR5D32 tissue for infection with a
panel of related R5X4 HIV-1 variants. 89.6 is a primary
patient isolate, while 89-v345.FL and 89-v345.SF are chi-
meric constructs that are isogenic to 89.6 except for the
V3-V5 region of gp120, which was replaced with corre-
sponding sequences from SF162 and JR-FL, respectively.
Each of these viruses efficiently uses both CCR5 and
CXCR4 in vitro based on fusion with and/or infection of
cell lines transfected with CD4 and the coreceptors
(Glushakova et al., 1999; Smyth et al., 1998).
We compared these viruses’ replication patterns in
CCR5D32 and control human tonsillar tissue. In normal
lymphoid tissue, each of the three viruses resulted in
productive infection and similar kinetics of replication: an
increase of p24 released into the media became evident
FIG. 2. Replication kinetics of HIV-1 in human lymphoid tissue from
infected with different HIV-1 strains, and virus replication was assessed
replication and to present average kinetics, data are presented as p
(means 6 SD for tissues from 7 to 25 donors in experiments with norm
the amount harvested at each time point was less than at the previous
p24 in CCR5D32 tissues infected with 89-v345.SF and SF162 as a perc
12 p.i.between Days 6 and 9 p.i. and replication continued at
least until Days 12–13 (Figs. 2c–2e). As we have de-scribed previously (Glushakova et al., 1997, 1998), the
absolute level of replication varies considerably in tis-
sues from different normal donors. In seven experiments,
the total production of p24 per tissue block ranged from
6 to 69 ng for 89.6, from 3 to 24 ng for 89-v345.SF, and
from 4 to 15 ng for 89-v345.FL. However, there was no
consistent difference among the three viruses in the
absolute level of replication in individual tissues. In
CCR5D32 and in normal lymphoid tissue, 89.6 and 89-
v345.FL replicated with similar kinetics (Figs. 2c and 2d).
The total production of p24 per block of CCR5D32 tissue
infected with 89.6 or 89-v345.FL was 47 and 6 ng, re-
spectively, which are within the range of production in
normal tissues. In contrast, 89-v345.SF did not replicate
in lymphoid tissue lacking CCR5 (Fig. 2e). Thus, 89-
v345.SF relies exclusively on CCR5 for infection and so
behaves as an R5 variant, while the two others variants
are not restricted to CCR5, and so seem to use CXCR4 in
addition to or instead of CCR5. Due to the scarcity of D32
donor tissue, for additional experiments, we used ex vivo
HIV-1-infected tissues from normal donors treated with
coreceptor ligands.
Sensitivity of dual-tropic HIV-1 variants to coreceptor
ligands
To confirm which coreceptor was used in normal lym-
phoid tissue that expresses both CCR5 and CXCR4, tis-
and CCR5-deficient donors. (a–e) Normal and CCR5D32 tissues were
measurements. To normalize for variation in the absolute level of viral
ges of the maximum p24 production at the last day of experiments
ues). 89-v345.SF and SF162 did not replicate in CCR5D32 tissues, and
oint. To demonstrate this in the same chart, we present the amount of
of what was produced by these two viruses in normal tissue on Daynormal
by p24
ercenta
al tiss
time psues from three normal donors were pretreated for 3 h
with or without the CXCR4-specific antagonist AMD3100,
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242 MALKEVITCH ET AL.the CCR5 ligand RANTES, or with a mixture of both, and
then infected as described above. Agents were replaced
as medium was changed every 3 days. To normalize for
donor-to-donor variation in the absolute level of viral
replication and to enable comparison of replication ki-
netics in experiments with tissues from different donors,
p24 production at each time point was expressed as a
percentage of maximum at the end of the experiments in
control viral infection. In all experiments, inhibition of
viral replication became evident at about Day 6 p.i. when
the concentration of p24 in controls generally increased
(Fig. 3).
The results of typical experiments are presented in
Figs. 3a–3i. Consistent with our previous data (Glusha-
kova et al., 1999), replication of 89.6 was completely
inhibited by AMD3100, with total p24 production in
FIG. 3. Inhibition of replication of 89.6 and its chimeras by CXCR4
and CCR5 ligands. RANTES (100 nM; a–c), AMD3100 (1 mg/ml; d–f), or
mixture of both (g–i) was added to the culture medium 3 h prior to
nfection with 89.6 (a, d, and g), 89-v345.SF (b, e, and h), or 89-v345.FL
c, f, and i). Ligands were replenished with every medium change. To
ormalize for variation in the absolute level of viral replication and to
resent average kinetics, data are presented as percentages of the
aximum p24 production at the last day of experiments. Typical repli-
ation curves from experiments with tissues from five to eight donors
re shown.AMD3100-treated cultures reduced to 3 6 1% of that in
control untreated infected tissue (n 5 7). In contrast, 89.6
w
creplication was not sensitive to RANTES (83 6 11% of
control p24 production; n 5 8). 89-v345.SF replication
was reduced by RANTES to 10 6 3% of control and by
AMD3100 to 60 6 7% of control (n 5 5), whereas repli-
ation of 89-v345.FL was reduced by AMD3100 and
ANTES to 34 6 12 and 42 6 14% of untreated infected
issue, respectively (n 5 6). Consistent with preferential
CR5 use by 89-v345.SF and CXCR4 use by 89.6,
ANTES reduced 89-v345.SF replication by approxi-
ately the same extent as it inhibited the CCR5-
estricted strain SF162, whereas inhibition of 89.6 by
MD3100 was similar to that of the CXCR4-restricted
train LAV.04 (data not shown). We also treated tissues
ith a combination of AMD3100 and RANTES. Since
MD3100 alone and RANTES alone resulted in near-
omplete inhibition of 89.6 and 89-v345.SF, respectively,
here was no additional inhibition seen with the addition
f the second agent (Figs. 3g and 3h). For 89-v345.FL,
owever, neither agent alone completely blocked infec-
ion but the combination of both agents did (Fig. 3i). Thus,
hese studies support the notion that 89.6 and 89-
345.SF are predominantly restricted in lymphoid tissue
o single coreceptors, CXCR4 and CCR5, respectively,
hereas 89-v345.FL uses both coreceptors. These re-
ults also show, as we reported earlier, that AMD3100 is
potent inhibitor of X4 but not R5 HIV variants in ex vivo
nfected human lymphoid tissue (Glushakova et al.,
999). In contrast, RANTES inhibits even completely
CR5-dependent R5 HIV-1 isolates by only 70–90%, but
oes not inhibit replication of X4 HIV variants (Glusha-
ova et al., 1999; Margolis et al., 1998).
oreceptor use in lymphoid tissue by other
ual-tropic primary isolates
These studies demonstrate an important distinction
etween coreceptor use in transfected cell lines in vitro
nd in lymphoid tissue ex vivo for a set of viruses related
o HIV-1 89.6. A critical question, however, is whether this
iscordance is unique to 89.6 or whether other primary
solates that use both coreceptors in vitro might also
how distinctive patterns in lymphoid tissue. Therefore,
o extend this analysis, we analyzed two additional pri-
ary isolates, 92US076 and 93US151, that exhibit R5X4
ual-tropic characteristics in vitro (the NIH AIDS Re-
earch and Reference Program). Because additional
CR5D32 lymphoid tissue was not available and since
he above studies had confirmed that pharmacological
nhibitors accurately identify coreceptor usage profiles in
he lymphoid microenvironment, we used AMD3100 and
ANTES to define the coreceptor usage profiles of
2US076 and 93US151 in lymphoid tissue ex vivo.
Replication by 93US151 was not inhibited by RANTES
total p24 production of 91 6 9% of control; n 5 3) butas almost completely blocked by AMD3100 (2 6 2% of
ontrol, n 5 3) or by AMD3100 plus RANTES (Fig. 4a). In
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243CORECEPTOR USE BY HIV-1 IN CCR5D32 LYMPHOID TISSUEcontrast, 92US076 was only partially inhibited by
AMD3100 to 37 6 7% of control (n 5 3). Although
92US076 was not significantly inhibited by RANTES
alone (95 6 28% of control; n 5 3), the addition of
ANTES to AMD3100 further inhibited 92US076 replica-
ion, reducing it approximately by 80% compared to con-
rol levels (Fig. 4b). The relatively poor 92US076 inhibition
y RANTES and residual 20% replication despite block-
de of both coreceptors likely reflect relative inefficient
ANTES blocking of CCR5 rather than an alternative
ntry pathway other than CCR5 and CXCR4. Thus, the
5X4 primary isolate 93US151, like 89.6, appears to uti-
ize CXCR4 exclusively for entry in lymphoid tissues,
hile 92US076, like 89-v345.FL, uses both coreceptors.
n contrast, 89-v345.SF relies predominantly on CCR5.
ytopathicity of dual-tropic HIV-1 variants in
CR5D32 and normal tissues
We next studied the correlation between coreceptor
tilization and cytopathicity of the HIV-1 variants by eval-
ating the cumulative CD41 T cell depletion over the
2–13 days of infection in CCR5D32 and normal tissues.
ince we have shown previously that CD81 T cells are
not depleted by ex vivo HIV-1 infection (Glushakova et al.,
1997), CD41 T cell depletion in these experiments was
evaluated as the decrease in CD41/CD81 ratio at Day
12–14 p.i. relative to matched uninfected control tissue
from the same donor.
As shown in Fig. 5a, 89.6 severely depleted CD41 T
cells in both normal and CCR5D32 lymphoid tissues. In
1
FIG. 4. Inhibition of HIV-1 primary isolates 92US076 (a) and 93US151
(b) by CXCR4 and CCR5 ligands. RANTES (100 nM), AMD3100 (1 mg/ml),
r a mixture of both was added to the culture medium as described in
he legend to Fig. 3. To normalize for variation in the absolute level of
iral replication and inhibition, data are presented as percentages of
he total p24 production in the course of the experiment relative to
ontrol infection (means 6 SD for tissues from three donors in exper-
ments with RANTES or AMD3100 and result of a single experiment
ith a mixture of RANTES and AMD3100).both tissue types, only ;20% of CD4 T cells remained at
Days 12–14 p.i. The monotropic X4 virus LAV.04 behaved
c
isimilarly and also severely depleted CD41 T cells, with
;2% of CD41 T cells remaining in CCR5D32 tissue and
4 6 2% remaining in LAV.04-infected normal tissue (Fig
5a). In contrast, depletion was milder in both CCR5D32
and normal tissues infected by 89-v345.FL, with about
60% of CD41 T cells remaining (Fig 5a). For dual-tropic
9.6, 89-v345.FL, and monotropic LAV.04 HIV-1 variants,
here was no statistical difference between normal and
CR5D32 tissues in the level of CD41 T cell depletion
(P , 0.33, P , 0.15, and P , 0.16, respectively). In
contrast, there was significant difference between CD41
T cell depletion in CCR5D32 and normal tissues infected
with 89-v345.SF or SF162 (P , 0.0007 and P , 0.0002,
espectively). No depletion was detected when CCR5D32
issue blocks were inoculated with 89-v345.SF or SF162
Fig. 5a), as expected since neither of these viruses
eplicated in the tissue lacking CCR5 (Figs. 2d and 2e). In
ormal tissue, 89-v345.SF infection resulted in mild de-
letion with 75–90% of CD41 T cells remaining (Fig. 5a),
similar to what was described for SF162 infection
(Glushakova et al., 1997, 1998). Tissues from four normal
donors were infected with primary isolates 92US076 and
93US151. Both 92US076 and 93US151 severely depleted
CD41 T cells in ex vivo infected tissues, resulting in
FIG. 5. CD41 T cell depletion in normal and CCR5D32 tissues
nfected ex vivo by HIV-1. Cells were mechanically isolated from unin-
ected and infected tissues, stained for CD45, CD3, CD4, and CD8, and
nalyzed with flow cytometry as described. Data are presented as
D41/CD81T cell ratio, relative to matched uninfected control tissue,
n Days 12–13 after infection by dual-tropic HIV-1 variants 89.6 and its
himeras as well as by control mono-tropic X4 isolate LAV.04 or R5
solate SF162 (a) or HIV-1 primary isolates 92US076 and 93US151 (b).
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244 MALKEVITCH ET AL.;10% of CD41 T cells remaining on 12–14 days after
nfection (Fig 5b). A mixture of AMD3100 and RANTES
revented CD41 T cell depletion in inoculated tissues,
onsistent with its inhibition of productive replication in
ymphoid tissue (data not shown).
DISCUSSION
HIV-1 coreceptor utilization analysis is generally
ased on the ability of virus to infect and/or fuse with cell
ines transfected with CD4 and coreceptor in vitro. So far
ore than a dozen coreceptors that support HIV or SIV
usion or infection in vitro have been identified (see
erger et al., 1999). Only CCR5 and CXCR4 are unequiv-
cally used in vivo, however (Bjorndal et al., 1997; Connor
t al., 1997; Dean et al., 1996; Huang et al., 1996; Liu et al.,
1996; Samson et al., 1996; Simmons et al., 1997), indicat-
ing that coreceptor function in vivo is more restricted
than studies in vitro would suggest. Dual-tropic R5X4
HIV-1 variants are defined as those that can enter cells in
vitro expressing either CCR5 or CXCR4 (Berger et al.,
1998), and initially it was assumed that HIV-1 variants
that use both major coreceptors in vitro would use the
same spectrum of coreceptors in other systems. Here
we asked what is the coreceptor specificity of the dual-
tropic viruses in human lymphoid tissue.
In previous studies, we showed that the R5X4 primary
isolate 89.6 is restricted mainly to CXCR4 in lymphoid
tissue despite efficient use of both CCR5 and CXCR4
entry pathways in vitro (Glushakova et al., 1999). We
report here a similar pattern with another R5X4 primary
isolate, 93US151. We also reported that a chimeric virus
that was R5X4 in vitro, 89-v345.SF, preferentially used
CCR5 in lymphoid tissue. Those conclusions were based
on inhibition by chemokine receptor blockade, however,
and are limited by the specificity and potency of such
agents. AMD3100 blocks CXCR4 with high potency and
specificity (Schols et al., 1997), whereas the b-chemo-
ines used to block CCR5 are considerably less efficient
nd specific (Margolis et al., 1998). Furthermore, RAN-
ES may potentially also influence viral replication
hrough other mechanisms besides CCR5 blockade (Kin-
er et al., 1998; Murphy et al., 2000). The present study
rovides a definitive answer to the question of CCR5
sage in tissue by dual-tropic isolates by utilizing lym-
hoid tissue naturally lacking CCR5 expression. Surpris-
ngly, only two of the five HIV-1 strains (and only one of
he three primary isolates tested) defined as R5X4 dual-
ropic in cell lines in vitro are truly dual-tropic in lymphoid
issue. Moreover, using this tissue, we answered
hether the absence of CCR5 expression (or presence
f the CCR5D32 mutant protein) affects the functional
bility of CXCR4 to mediate HIV-1 infection. Analysis of
inetics of viral replication of LAV.04, 89.6, and 89v-345
L revealed no difference between infection of CCR5D32
nd normal lymphoid tissue.Thus, we confirm and extend the observation that use
f CCR5 and CXCR4 by primary isolates in lymphoid
issue ex vivo is more restricted than in cell lines in vitro.
Recently, Zhang et al. (2000) reported that an SIV/HIV
recombinant virus containing the 89.6 Env was restricted
to CXCR4 for infection of PBMC in vitro suggesting that
coreceptor choice in primary lymphocytes in vitro may
also be restricted compared with transfected cells. They
also found that AMD3100 completely blocked infection of
CCR5-negative PBMC by several strains that could use a
variety of secondary coreceptors such as STRL33,
CX3CR1, CCR8, and Apj in transfected cells (Zhang and
Moore, 1999), which argued that the secondary corecep-
tors were unlikely to be relevant pathways for infection in
vivo or necessary targets for coreceptor-targeted antivi-
ral strategies. Our results provide further support for that
notion by extending it to the context of the natural lym-
phoid microenvironment. 89-v345.SF uses two corecep-
tors in vitro but fails to infect CCR5D32 tissue. Strain 89.6
uses a wide variety of secondary coreceptors in vitro
such as CCR2, CCR3, CCR8, and Apj (Doranz et al., 1996;
Edinger et al., 1998; Rucker et al., 1997) but was com-
pletely blocked by AMD3100 in our system. This result
indicates that the alternative coreceptors are not used by
this strain for infection of lymphoid tissue ex vivo. We
have not specifically examined expression of the other
coreceptors in our system, so our data do not exclude
their usage by HIV-1 strains in other compartments
where they may be particularly highly expressed (He et
al., 1997; Lee et al., 2000). For example, a recent study
using human thymocytes suggested that entry into those
cells could be mediated by an alternative coreceptor,
possibly CCR8 (Lee et al., 2000).
The mechanisms responsible for restricted CCR5 and
CXCR4 utilization ex vivo are not clear. One possibility is
that the expression of a particular coreceptor in tissue
may be too low to mediate efficient entry, thus restricting
an otherwise dual-tropic virus to only one coreceptor,
while in transfected cell lines the level of expression may
be higher. However, this would not explain why in sam-
ples of the same tissue some viruses are restricted to
one coreceptor while other strains are restricted to the
other. Alternatively, two coreceptors may be equally well
expressed in lymphoid tissue but differently arranged
relative to CD4 (Xiao et al., 1999) or exist in distinct
conformations (Lee et al., 1999) that support entry by
some but not other strains. Yet another possibility is that
differences in the viral Env glycoprotein may be respon-
sible for distinct coreceptor utilization in lymphoid tissue
ex vivo versus cells in vitro. Since replication involves
multiple rounds of virus production and re-infection in
lymphoid tissue, each round of infection subsequent to
the initial inoculum is supported by virions produced
within the infected tissues. It is conceivable that the
conformation or surface density of Env glycoprotein on
virions produced by host cells in the native microenvi-
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245CORECEPTOR USE BY HIV-1 IN CCR5D32 LYMPHOID TISSUEronment may differ from Env on transfected cells or
virions produced in vitro, leading to distinct coreceptor
fusion capacities. Finally, distinct coreceptor-mediated
infection by these strains may potentially result from
differences in postfusion steps of infection. Env has been
shown to interact with coreceptors to deliver signals to
target cells (Davis et al., 1997; Liu et al., 2000; Weissman
t al., 1997), and in several systems Env–coreceptor
nteractions may influence postentry steps of infection
Chackerian et al., 1997; Mori et al., 1993). Unlike in vitro
BMC infection studies, these tissues are not subjected
o exogenous activation and stimulation (Glushakova et
l., 1995, 1997, 1998). Although coreceptor use in stimu-
ated PBMC may also differ from that in transfected cell
ines (Zhang et al., 2000; Zhang and Moore, 1999), it is
ossible that differences between viruses in signals
ransmitted to target cells through CCR5 and CXCR4
ould determine whether permissive interactions occur
t postentry stages of infection in lymphoid tissue. What-
ver the mechanisms of preferential utilization of a par-
icular coreceptor by a dual-tropic isolate, coreceptor
hoice apparently determines viral cytopathicity in ex
ivo infected human lymphoid tissue.
Since the ex vivo lymphoid tissue model more closely
ecapitulates the natural viral reservoir in vivo than do
ransfected cells, our results suggests that major core-
eptor usage is more restricted in vivo compared with
hat is suggested by in vitro studies. Like any experi-
ental model, however, the ex vivo infected human lym-
hoid tissue has certain limitations, and results should
e extrapolated to the situation in vivo with caution.
lthough it reflects the complex cytoarchitecture of lym-
hoid tissue where critical events in HIV infection occur
n vivo more faithfully than PBMC cultures, the model
oes not simulate the immune response of an infected
ndividual. Such an immune response could modulate
CR5 and CXCR4 expression and alter coreceptor dis-
ribution among CD41 T cells in lymphoid tissues of
nfected individuals compared to ex vivo. However, since
oth CCR5 and CXCR4 are expressed by CD41 T cells in
he ex vivo tissues sufficiently for R5 and X4 HIV-1 infec-
ion (Grivel and Margolis, 1999), it is not the lack of the
ppropriate coreceptor that makes dual-tropic viruses
ehave as mono-tropic in lymphoid tissue ex vivo.
In summary, the experiments on ex vivo infection of
ormal and CCR5D32 human lymphoid tissue presented
bove prove genetically that dual tropism as defined in
itro using cell lines expressing either CCR5 or CXCR4 is
ot fully predictive of coreceptor usage in human lym-
hoid tissue ex vivo and confirm previous conclusions
ased on pharmacologic methods. The results indicate
hat the switch of coreceptor tropism in vivo during the
ourse of HIV-1 disease may be more complex than that
uggested by coreceptor use as reflected in in vitro
ssays. Moreover, our results indicate that CCR5D32
omozygosity does not affect CXCR4 coreceptor functionn primary lymphoid tissue, suggesting that the absence
f CCR5, and not other indirect pathways, is the key
actor responsible for HIV resistance in individuals with
his genotype. Furthermore, viruses that use CXCR4 ex-
lusively or in addition to CCR5 are highly cytopathic,
hile those using exclusively CCR5 are mildly patho-
enic, indicating that coreceptor selectivity in the lym-
hoid tissue may be the principal factor responsible for
ccelerated disease progression. The more restricted
ajor coreceptor utilization and apparent lack of minor
oreceptor utilization in lymphoid tissue ex vivo thus may
ffer cause for optimism regarding the ability to effec-
ively inhibit HIV-1 replication in vivo through entry core-
ceptor blockade.
MATERIALS AND METHODS
Viruses
We used the R5X4 prototype dual-tropic isolate 89.6
(Collman et al., 1992; Doranz et al., 1996), two additional
R5X4 primary isolates 92US076 and 93US151 (obtained
from the National Institutes of Health AIDS Research and
Reference Program), along with the monotropic X4 strain
LAV.04 and R5 strain SF162. We also used two viral
chimeras, 89-v345.FL and 89-v345.SF, in which the V3
through V5 env region of 89.6 was replaced with se-
quences from JR–FL or SF162, respectively, as previously
described (Smyth et al., 1998). Both chimeric viruses
were R5X4 as evidenced by the ability to mediate fusion
and infection of cell lines transfected with CD4 and either
CCR5 or CXCR4 (Glushakova et al., 1999; Smyth et al.,
1998).
Infection of human lymphoid tissue ex vivo
Human tonsils were obtained from patients undergo-
ing tonsillectomy, dissected into ;2-mm blocks, and
incubated on collagen gel at the air–liquid interface as
described earlier (Glushakova et al., 1997, 1998; Margolis
et al., 1998). Medium was changed every 2–3 days, and
additional details of culture method were previously de-
scribed (Glushakova et al., 1997, 1998; Margolis et al.,
1998). Lymphoid tissue blocks were infected using 3–5
ml clarified virus-containing medium applied slowly on
top of each tissue block. The dose of infection was
chosen so that productive replication in tissue started
between Days 3 and 6 p.i. and continued to increase in
the course of the 12- to 14-day experiment (Glushakova
et al., 1997, 1998). The amount of viral p24 Gag antigen
used to inoculate each tissue block was ;100 pg for
LAV.04, 45 pg for SF162, between 50 and 400 pg for
different stocks of 89.6, 600 pg and 1.1 ng in two different
stocks of 89-v345.SF, and 180 pg and 1.1 ng for two
different stocks of 89-v345.FL. For 92US076, the dose
was 100 pg and for 93US151 was 300 pg. RANTES
(PeproTech, Rocky Hill, NJ) and AMD3100 [obtained from
w
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246 MALKEVITCH ET AL.G. Henson, AnorMED, Langley, BC (Donzella et al., 1998;
Schols et al., 1997) or as a generous gift from J. Moore]
were added to the medium bathing tissue blocks 3 h
prior to infection at concentrations of 100 nM and 1
mg/ml, respectively, and replenished with each medium
change. The concentration of p24 gag antigen in the
medium was measured by ELISA (Beckman Coulter, Mi-
ami, FL, or NCI, Frederick, MD).
Depletion of CD41 T cells
Cells were mechanically isolated from tissue blocks
on Days 12 to 14 p.i. and stained with a mixture of
anti-CD3-FITC, anti-CD4-APC, and anti-CD8-TC monoclo-
nal antibodies (Caltag, Burlingame, CA) as described
(Glushakova et al., 1998, 1999; Grivel and Margolis,
1999). To analyze coreceptor expression on CD41 T lym-
phocytes, cells were stained with anti-CD3-FITC and
CD4 TriColor (Caltag) as well as with anti-CXCR4-APC
and anti-CCR5-PE (Pharmingen), and analyzed using a
FACS calibur (Becton Dickinson, San Jose, CA). To nor-
malize for differences in the size and cellularity of tissue
blocks, depletion of total CD41 T cells and T cell subsets
as expressed as a ratio of the number of these cells to
he number of CD81 T cells, which are not affected by
nfection (Glushakova et al., 1997).
enotyping of the CCR5D32 allele
Genomic DNA was isolated from two individuals of
nown CCR5 genotype and from tonsillar tissue of CCR5-
egative phenotype. Approximately 200 ng of DNA was
mplified by PCR in a 50-ml reaction using 1.5 U Platinum
aq (Life Technologies, Rockville, MD), 2 mM MgCl2, 175
mM of each dNTP, and 15 pM of each primer (59-GTC TTC
ATT ACA CCT GCA GCT CTC-39 and 59-GGT CCA ACC
TGT TAG AGC TAC TGC-39). Amplification was performed
with 35 cycles of 1 min at 95, 65, and 72°C, preceded by
95°C for 3 min and followed by 72°C for 10 min. Ampli-
fication products were resolved by 2% agarose gel elec-
trophoresis and stained with ethidium bromide.
ACKNOWLEDGMENTS
This work was supported in part by the National Aeronautics and
Space Administration/National Institutes of Health Center for Three-
Dimensional Tissue Culture (L.M.) and by NIH Grants MH-61139 and
AI-35502 (R.G.C.).
REFERENCES
Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T., Littman, D. R.,
Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J., and
Weiss, R. A. (1998). A new classification for HIV-1. Nature 391, 240.
erger, E., A., Murphy, P., M., and Farber, J. M. (1999). Chemokine
receptors as HIV-1 coreceptors: Roles in viral entry, tropism and
disease. Annu. Rev. Immunol. 17, 657–700.
jorndal, A., Deng, H., Jansson, M., Fiore, J. R., Colognesi, C., Karlsson,
A., Albert, J., Scarlatti, G., Littman, D. R., and Fenyo, E. M. (1997).
Coreceptor usage of primary human immunodeficiency virus type 1
Hisolates varies according to biological phenotype. J. Virol. 71, 7478–
7487.
Chackerian, B., Long, E. M., Luciw, P. A., and Overbaugh, J. (1997).
Human immunodeficiency virus type 1 coreceptors participate in
postentry stages in the virus replication cycle and function in simian
immunodeficiency virus infection. J. Virol. 71, 3932–3939.
ollman, R., Balliet, J. W., Gregory, S. A., Friedman, H., Kolson, D. L.,
Nathanson, N., and Srinivasan, A. (1992). An infectious molecular
clone of an unusual macrophage-tropic and highly cytopathic strain
of human immunodeficiency virus type 1. J. Virol. 66, 7517–7521.
onnor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., and Landau, N. R.
(1997). Change in coreceptor use coreceptor use correlates with
disease progression in HIV-1–infected individuals. J. Exp. Med. 185,
621–628.
avis, C. B., Dikic, I., Unutmaz, D., Hill, C. M., Arthos, J., Siani, M. A.,
Thompson, D. A., Schlessinger, J., and Littman, D. R. (1997). Signal
transduction due to HIV-1 envelope interactions with chemokine
receptors CXCR4 or CCR5. J. Exp. Med. 186, 1793–1798.
ean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W.,
Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomp-
erts, E., Donfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C.,
Detels, R., and SJ, O. B. (1996). Genetic restriction of HIV-1 infection
and progression to AIDS by a deletion allele of the CKR5 structural
gene. Hemophilia Growth and Development Study, Multicenter AIDS
Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco
City Cohort, ALIVE Study. Science 273, 1856–1862.
Donzella, G. A., Schols, D., Lin, S. W., Este, J. A., Nagashima, K. A.,
Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., De Clercq, E.,
and Moore, J. P. (1998). AMD3100, a small molecule inhibitor of HIV-1
entry via the CXCR4 co- receptor. Nat. Med. 4, 72–77.
Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C.,
Parmentier, M., Collman, R. G., and Doms, R. W. (1996). A dual-tropic
primary HIV-1 isolate that uses fusin and the beta-chemokine recep-
tors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149–
1158.
Edinger, A. L., Hoffman, T. L., Sharron, M., Lee, B., Yi, Y., Choe, W.,
Kolson, D. L., Mitrovic, B., Zhou, Y., Faulds, D., Collman, R. G.,
Hesselgesser, J., Horuk, R., and Doms, R. W. (1998). An orphan
seven-transmembrane domain receptor expressed widely in the
brain functions as a coreceptor for human immunodeficiency virus
type 1 and simian immunodeficiency virus. J. Virol. 72, 7934–7940.
Glushakova, S., Baibakov, B., Margolis, L. B., and Zimmerberg, J. (1995).
Infection of human tonsil histocultures: A model for HIV pathogene-
sis. Nat. Med. 1, 1320–1322.
Glushakova, S., Baibakov, B., Zimmerberg, J., and Margolis, L. (1997).
Experimental HIV infection of human lymphoid tissue: Correlation of
CD41 T cell depletion and virus syncytium-inducing/non-syncytium-
inducing phenotype in histoculture inoculated with laboratory strains
and patient isolates of HIV type 1. AIDS Res. Hum. Retroviruses 13,
461–471.
lushakova, S., Grivel, J. C., Fitzgerald, W., Sylwester, A., Zimmerberg, J.,
and Margolis, L. B. (1998). Evidence for the HIV-1 phenotype switch
as a causal factor in acquired immunodeficiency. Nat. Med. 4, 346–
349.
lushakova, S., Yi, Y., Grivel, J. C., Singh, A., Schols, D., De Clercq, E.,
Collman, R. G., and Margolis, L. (1999). Preferential coreceptor utili-
zation and cytopathicity by dual-tropic HIV-1 in human lymphoid
tissue ex vivo. J. Clin. Invest. 104, R7–R11.
rivel, J. C., and Margolis, L. B. (1999). CCR5- and CXCR4-tropic HIV-1
are equally cytopathic for their T-cell targets in human lymphoid
tissue. Nat. Med. 5, 344–346.
e, J., Chen, Y., Farzan, M., Choe, H., Ohagen, A., Gartner, S., Busciglio,
J., Yang, X., Hofmann, W., Newman, W., Mackay, C. R., Sodroski, J., and
Gabuzda, D. (1997). CCR3 and CCR5 are co-receptors for HIV-1
infection of microglia. Nature 385, 645–649.uang, Y., Paxton, W. A., Wolinsky, S. M., Neumann, A. U., Zhang, L., He,
T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., Kunstman, K.,
247CORECEPTOR USE BY HIV-1 IN CCR5D32 LYMPHOID TISSUEErickson, D., Dragon, E., Landau, N. R., Phair, J., Ho, D. D., and Koup,
R. A. (1996). The role of a mutant CCR5 allele in HIV-1 transmission
and disease progression. Nat Med 2, 1240–1243.
Kinter, A., Catanzaro, A., Monaco, J., Ruiz, M., Justement, J., Moir, S.,
Arthos, J., Oliva, A., Ehler, L., Mizell, S., Jackson, R., Ostrowski, M.,
Hoxie, J., Offord, R., and Fauci, A. S. (1998). CC-chemokines enhance
the replication of T-tropic strains of HIV-1 in CD4(1) T cells: Role of
signal transduction. Proc. Natl. Acad. Sci. USA 95, 11880–11885.
Lee, B., Sharron, M., Blanpain, C., Doranz, B. J., Vakili, J., Setoh, P., Berg,
E., Liu, G., Guy, H. R., Durell, S. R., Parmentier, M., Chang, C. N., Price,
K., Tsang, M., and Doms, R. W. (1999). Epitope mapping of CCR5
reveals multiple conformational states and distinct but overlapping
structures involved in chemokine and coreceptor function. J. Biol.
Chem. 274, 9617–9626.
Lee, S., Tiffany, H. L., King, L., Murphy, P. M., Golding, H., and Zaitseva,
M. B. (2000). CCR8 on human thymocytes functions as a human
immunodeficiency virus type 1 coreceptor. J. Virol. 74, 6946–6952.
Liu, Q. H., Williams, D. A., McManus, C., Baribaud, F., Doms, R. W.,
Schols, D., De Clercq, E., Kotlikoff, M., I, Collman, R. G., and Freed-
man, B. D. (2000). HIV-1 gp120 and chemokines activate ion channels
in primary macrophages through CCR5 and CXCR4 stimulation. Proc.
Natl. Acad. Sci. USA 97, 4832–4837.
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R.,
MacDonald, M. E., Stuhlmann, H., Koup, R. A., and Landau, N. R.
(1996). Homozygous defect in HIV-1 coreceptor accounts for resis-
tance of some multiply-exposed individuals to HIV-1 infection. Cell
86, 367–377.
Locati, M., and Murphy, P. M. (1999). Chemokines and chemokine
receptors: Biology and clinical relevance in inflammation and AIDS.
Annu. Rev. Med. 50, 425–40.
Margolis, L. B., Glushakova, S., Grivel, J. C., and Murphy, P. M. (1998).
Blockade of CC chemokine receptor 5 (CCR5)-tropic human immu-
nodeficiency virus-1 replication in human lymphoid tissue by CC
chemokines. J. Clin. Invest. 101, 1876–1880.
Mori, K., Ringler, D. J., and Desrosiers, R. C. (1993). Restricted replica-
tion of simian immunodeficiency virus strain 239 in macrophages is
determined by env but is not due to restricted entry. J. Virol. 67,
2807–2814.
Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R.,
Matsushima, K., Miller, L. H., Oppenheim, J. J., and Power, C. A.
(2000). International union of pharmacology. XXII. Nomenclature for
chemokine receptors. Pharmacol. Rev. 52, 145–176.
Rucker, J., Edinger, A. L., Sharron, M., Samson, M., Lee, B., Berson, J. F.,
Yi, Y., Margulies, B., Collman, R. G., Doranz, B. J., Parmentier, M., and
Doms, R. W. (1997). Utilization of chemokine receptors, orphan re-
ceptors, and herpesvirus- encoded receptors by diverse human and
simian immunodeficiency viruses. J. Virol. 71, 8999–9007.
Samson, M., Labbe, O., Mollereau, C., Vassart, G., and Parmentier, M.
(1996). Molecular cloning and functional expression of a new human
CC-chemokine receptor gene. Biochemistry 35, 3362–3367.Scarlatti, G., Tresoldi, E., Bjorndal, A., Fredriksson, R., Colognesi, C.,
Deng, H. K., Malnati, M. S., Plebani, A., Siccardi, A. G., Littman, D. R.,
Fenyo, E. M., and Lusso, P. (1997). In vivo evolution of HIV-1 co-
receptor usage and sensitivity to chemokine-mediated suppression.
Nat. Med. 3, 1259–1265.
Schols, D., Struyf, S., Van Damme, J., Este, J. A., Henson, G., and De
Clercq, E. (1997). Inhibition of T-tropic HIV strains by selective an-
tagonization of the chemokine receptor CXCR4. J. Exp. Med. 186,
1383–1388.
Simmons, G., Clapham, P. R., Picard, L., Offord, R. E., Rosenkilde, M. M.,
Schwartz, T. W., Buser, R., Wells, T. N. C., and Proudfoot, A. E. (1997).
Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes
by a novel CCR5 antagonist. Science 276, 276–279.
Simmons, G., Wilkinson, D., Reeves, J. D., Dittmar, M. T., Beddows, S.,
Weber, J., Carnegie, G., Desselberger, U., Gray, P. W., Weiss, R. A., and
Clapham, P. R. (1996). Primary, syncytium-inducing human immuno-
deficiency virus type 1 isolates are dual-tropic and most can use
either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70,
8355–8360.
Smyth, R. J., Yi, Y., Singh, A., and Collman, R. G. (1998). Determinants of
entry cofactor utilization and tropism in a dualtropic human immu-
nodeficiency virus type 1 primary isolate. J. Virol. 72, 4478–4484.
Tersmette, M., Lange, J. M., de Goede, R. E., de Wolf, F., Eeftink-
Schattenkerk, J. K., Schellekens, P. T., Coutinho, R. A., Huisman, J. G.,
Goudsmit, J., and Miedema, F. (1989). Association between biological
properties of human immunodeficiency virus variants and risk for
AIDS and AIDS mortality. Lancet 1, 983–985.
Weissman, D., Rabin, R. L., Arthos, J., Rubbert, A., Dybul, M., Swofford,
R., Venkatesan, S., Farber, J. M., and Fauci, A. S. (1997). Macrophage-
tropic HIV and SIV envelope proteins induce a signal through the
CCR5 chemokine receptor. Nature 389, 981–985.
Wu, L., Paxton, W. A., Kassam, N., Ruffing, N., Rottman, J. B., Sullivan, N.,
Choe, H., Sodroski, J., Newman, W., Koup, R. A., and Mackay, C. R.
(1997). CCR5 levels and expression pattern correlate with infectabil-
ity by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185, 1681–1691.
Xiao, X., Wu, L., Stantchev, T. S., Feng, Y. R., Ugolini, S., Chen, H., Shen,
Z., Riley, J. L., Broder, C. C., Sattentau, Q. J., and Dimitrov, D. S. (1999).
Constitutive cell surface association between CD4 and CCR5. Proc.
Natl. Acad. Sci. USA 96, 7496–7501.
Zhang, Y., Lou, B., Lal, R. B., Gettie, A., Marx, P. A., and Moore, J. P.
(2000). Use of inhibitors to evaluate coreceptor usage by simian and
simian/human immunodeficiency viruses and human immunodefi-
ciency virus type 2 in primary cells. J. Virol 74, 6893–6910.
Zhang, Y., and Moore, J. P. (1999). Will multiple coreceptors need to be
targeted by inhibitors of human immunodeficiency virus type 1 entry?
J. Virol 73, 3443–3448.
Zhu, T., Mo, H., Wang, N., Nam, D. S., Cao, Y., Koup, R. A., and Ho, D. D.
(1993). Genotypic and phenotypic characterization of HIV-1 patients
with primary infection. Science 261, 1179–1181.
